An Open-Label, Single-Dose, 4-Way Crossover, Bioavailability Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Food Effect of BBI-5000 Capsules in Healthy Adult Subjects
Phase of Trial: Phase I
Latest Information Update: 04 Dec 2015
At a glance
- Drugs BBI 5000 (Primary)
- Indications Atopic dermatitis
- Focus Pharmacokinetics
- Sponsors Brickell Biotech
- 01 Dec 2015 Status changed from recruiting to completed, according to ClinicalTrials.gov record.
- 28 Oct 2015 Status changed from planning to recruiting, as reported by ClinicalTrials.gov.
- 11 Feb 2015 New trial record